A new drug application for Dasynoc, a protein kinase inhibitor product candidate for patients with chronic myeloid leukemia, has been accepted by the FDA.

Related Keywords

Xspray Pharma , , Prescription Drug User Fee Act , Accessed February , Hematologic Oncology , News ,